We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

Shares of GSK plc (LON:GSK – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One research ...

Impact of China on Healthcare R&D and the Growing Potential of Undervalued ... beating its benchmark by 218 percentage points (see more details here). GSK plc (NYSE:GSK) tops our list for being ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...

GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries. The initiative will focus on vaccines and ...

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...